SEC
APLS

Seven Eight Capital’s Apellis Pharmaceuticals APLS Stock Holding History

Seven Eight Capital’s Portfolio APLS Stock Details APLS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-7,101
Closed -$272K – 704
2024
Q2 		$272K Sell
7,101
-11,341
-61% -$514K 0.03% 617
2024
Q1 		$1.08M Buy
+18,442
New +$1.18M 0.11% 279
2023
Q4 		– Sell
-22,188
Closed -$844K – 614
2023
Q3 		$844K Buy
+22,188
New +$975K 0.1% 284
2020
Q4 		– Sell
-11,769
Closed -$355K – 404
2020
Q3 		$355K Buy
+11,769
New +$352K 0.08% 421

Other funds holding APLS

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return

Seven Eight Capital's APLS Position: Q3 2024 in Review

Seven Eight Capital sold out of Apellis Pharmaceuticals (APLS) in Q3 2024, closing a stake of 7,101 shares — an estimated $272K sold.

Seven Eight Capital first reported a position in APLS in Q3 2020 and held it in 4 quarters. The position peaked at $1.08M in Q1 2024. 265 funds tracked by Wall St. Rank hold APLS as of Q3 2024.

  • Seven Eight Capital reported no remaining Apellis Pharmaceuticals position as of Q3 2024 after selling out during the quarter.
  • Seven Eight Capital sold 7,101 Apellis Pharmaceuticals shares in Q3 2024, an estimated $272K.
  • Seven Eight Capital first reported a position in Apellis Pharmaceuticals in Q3 2020 and held it in 4 quarters.
  • Seven Eight Capital's Apellis Pharmaceuticals position peaked at $1.08M in Q1 2024.
  • 265 funds tracked by Wall St. Rank held Apellis Pharmaceuticals as of Q3 2024.

Based on Seven Eight Capital's 13F filing for Q3 2024, filed 12 Nov 2024.